News by subject: TRI

ResoTher Pharma, a biotech company focused on developing life-saving options for patients suffering from cardiovascular disease, today announced that the company has received a ?2.5 million grant from the European Innovation Council (EIC) to support...

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor, was given on top of empagliflozin, an SGLT2 inhibitor, suggesting additive...

A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis. Whole genome sequence data from Iceland and...

This?information?is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by,?nor a part of, the American College of Rheumatology.  30+ presentations of studies funded by the LRA spanning a broad spectrum of...

Rampart Health, a company dedicated to harnessing the abscopal effect for cure in patients with metastatic cancer, announced positive preliminary results of the first-ever prospective trial of a novel treatment delivered directly into cancer at the...

SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at the upcoming Society for Melanoma Research Congress in Philadelphia. Dr. M.E. Egger's presentation...

EpicentRx, Inc. ("EpicentRx"), a clinical-stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, has been selected for oral and poster presentations at the prestigious Society for Neuroscience's...

Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...

Wound management is essential to ensure a speedy and safe recovery, and tissue adhesive patches are an attractive option that can replace sutures and stapling. In a recent study, researchers from Korea developed a new type of gelatin-based tissue...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has completed dosing of the last patient in the double-blind segment of its Phase 2b...

NetraMark Holdings Inc. (the "Company" or "NetraMark")  is pleased to announce the appointment of Dr. Larry Alphs as its Chief Medical Officer (CMO). Dr. Alphs will play an important role in shaping the company's initiatives, further strengthening...

I-Mab (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced...

IceCure Medical Ltd. ("IceCure" or the...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is set to unveil seven significant abstracts at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place from...

PhaseV, a pioneer in causal machine learning (ML) for dynamic clinical trial analysis and optimization, announced today it has partnered with biopharma marketplace 9xchange, to bring PhaseV's technology to 9xchange's connected ecosystem transaction...

Takeda Canada Inc. ("Takeda") is pleased to announce that Canadian Blood Services (CBS) has included HyQvia® (Normal Immunoglobulin [Human]) 10% & Recombinant Human Hyaluronidase solution for subcutaneous infusion) as replacement therapy for primary...

The ERP Biomarker Qualification Consortium announced today that they will be presenting data from a recently completed, pharma industry sponsored study that measured the electrophysiologic effects of ketamine on healthy brain function, at the CNS...

COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patientsCOM701 dual and triple combinations mediated clinical benefit in platinum resistant...

Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies, unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SITC) conference. The study evaluated the ability of...

Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated long-term...

NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", (NRx), a clinical-stage...

Recently, the results of the Phase I study for iparomlimab (R&D code: QL1604), developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journal Frontiers in Immunology (2022 Impact Factor: 7.3). The title of the paper is "A...

Cellenkos® Inc., a clinical stage biotechnology company focused on...

Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study.With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate differentiated durability.Following dialogue with US...

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a poster presentation detailing additional data from a Phase II trial of...

Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42, a novel farnesoid X receptor (FXR) agonist, in healthy...

GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug...

On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. KGX101 is a recombinant IL-12 Fc fusion protein designed for intravenous injection. The...

Astellas Pharma...

Promontory Therapeutics Inc., a Phase 2 stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability...

ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse eventsDose level 2 prevented disease progression and reduced vision-threatening events in non-proliferative...

Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced the presentation of preclinical data on highly potent Series 2 nucleotide...

Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets will present multispecific molecules targeting GPRC5D, BCMA, and CD3 this week during the Society for Immunotherapy of Cancer (SITC)...

Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today presented the first proof-of-concept data on its...

Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today revealed molecular real-world data (RWD) demonstrating that high PPARG expression in...

Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Defeat Duchenne Canada, Canada's leading charity fighting to defeat Duchenne, today announced a...

Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual...

Florida Cancer Specialists & Research Institute (FCS) physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego. They will join stakeholders across the immune-oncology field worldwide to advance the...

Sumitomo Pharma America, Inc. (SMPA) today announced preliminary clinical data for investigational agents TP-3654, a selective oral PIM1 kinase inhibitor, and DSP-5336, an inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction....

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced the presentation of...

T3D Therapeutics presented top-line results from its Phase 2 PIONEER study at the 16th international conference on Clinical Trials in Alzheimer's Disease (CTAD). The double-blind study compared 3 doses of T3D-959 versus placebo administered orally...

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces abstract data to be presented at the 65th American Society of Hematology (ASH)...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaftoclax (APG-2575),...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the company's novel...

Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness.The interim Phase 2a...

Lilly Canada is pleased to announce that Mounjaro®...

?  NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR  ? ?  mNPM1 final efficacy data from the Phase 1 portion of AUGMENT-101 demonstrates a 36% CR/CRh rate  ? ?  Revumenib and axatilimab U.S. registrational filings on...

Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today its schedule of activities at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting from November 26-30...

MyOme, Inc., a pioneering clinical whole genome platform analysis company specializing in polygenic risk scores, will present data during the 2023 American Society of Human Genetics (ASHG) Annual Meeting taking place from...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company")  a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it has selected of Fortrea (FTRE) as the Company's...